Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on ART
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This is a phase I, single-site, study to evaluate the effects of VOR and HIV-1 Antigen
Expanded Specific T Cell Therapy (HXTC) on persistent HIV-1 Infection in HIV-infected
individuals suppressed on ART. Twelve participants with durable viral suppression will be
enrolled and will complete the study. All participants will receive the same treatment and if
eligible, will be dosed with HXTC and VOR. Participants will continue their baseline ART
regimen throughout the study.